BioSpace News Archive

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2020.

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM) serving commercial, Medicare and Medicaid segments, announces today its strategic collaboration with Summit Reinsurance Services, Inc. (Summit Re), a managing general underwriter and reinsurance advisor, to provide innovative specialty drug programs to address the high costs of specialty pharmacy claims.

Rafarma Pharmaceuticals, Inc. “OTC:” is pleased to announce that it has established a new corporate entity in Thailand.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and B. Braun Medical Inc., a global market leader1 in regional anesthesia and pain management, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Onvision®, a breakthrough ultrasound guidance solution for real-time needle tip tracking.

New Foundation grant to fund innovative projects, national convenings and education programs that will enhance the skills of all health care providers and improve the experience of patients

A recent study has concluded that WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous cells in the esophagus, is a cost-effective adjunct to forceps biopsies when screening for Barrett’s esophagus (BE).

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), today announced that it has engaged with certain shareholders to enter into voluntary lock-up agreements (the “Lock-up Agreements”) applying resale restrictions on up to 52,908,420 common shares (the “Restricted Shares”) extending the period of time before the shares become free trading.

ADA Leads 20 National Patient Advocate Groups Urging USPS Delivery Improvements

Fixx Pharmaceuticals Inc is a new biotechnology company launching on September 1, 2020.

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2021 on September 1, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific